Forbes Publish Date: Nov 22, 2022 Harvard trained surgeon and big data entrepreneur Dr. Richard Gliklich has been working to improve the management of chronic conditions by organising, analysing and applying health outcomes data since 1999. Currently he is the founder and CEO of OM1 (pronounced Ohm-one). The company is a health outcomes and registries[…]
Springer Link Publish Date: November 4, 2022 Read the Full Article >> Abstract Background There is limited evidence on the clinical and economic benefit of achieving disease control in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), thus we aimed to assess the impact of disease control on healthcare resource use (HCRU) and direct medical[…]
Bloomberg Law Publish Date: November 14, 2022 Read the Full Article >> More than half of women ages 15 to 49 who use a common arthritis drug risk losing access under restrictive state abortion laws, according to a new study based on nationwide health-care data. The analysis, published Saturday in the Arthritis & Rheumatology Journal, found[…]
AdvaMed Publish Date: November 3, 2022 Read the Full Article>> Challenges of AI in MedTech In the medical device space, powerful insights from real-world data can seem ‘just out of reach’. Capturing patient characteristics and outcomes, at scale and with consistency over time, is challenging outside of clinical trials. Personalization – bridging the gap between[…]
Listen to OM1’s podcast episode on the Medical Affairs Professional Society (MAPS) “Elevate” podcast series. Dr. Carl Marci is discussing the use of Real-World Data and Real-World Evidence to understand and possibly intercede in treatment-resistant depression and why it is especially difficult to develop treatments against resistant depression using the traditional structure of R&D-led clinical[…]
